Similarly, treatment with pembrolizumab resulted in comparable OS outcomes between patients older and younger than 65 with PD-L1-expressing, advanced and untreated NSCLC in the randomized phase III study KEYNOTE-042 [13]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.